Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51

Benzinga Newsdesk www.benzinga.com Neutral 71.1%

Neg 0% Neu 71.1% Pos 0%

Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $51.